Koordinierung und Durchführung der deutschen Beteiligung der WHO Studie Solidarity gemäß den WHO Protokollen

  • Funded by Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Total publications:0 publications

Grant number: 01KI2067A

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $856,495.08
  • Funder

    Bundesministerium für Bildung und Forschung [German Federal Ministry of Education and Research] (BMBF)
  • Principle Investigator

    Pending
  • Research Location

    Germany, Europe
  • Lead Research Institution

    Justus-Liebig-University GieÇ­en
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The aim of the project is to enable German clinics to participate in international clinical trials that are already testing known drugs for the treatment of COVID-19. These studies include, for example, the "Solidarity Trial of the WHO" or the comparable DisCOVery Trial under the leadership of the French Institute de la Santé et de la Recherche Médicale (INSERM). These studies are intended to test specific active substances in as many clinics and as many countries as possible on a large number of patients, for which there are first indications of effectiveness against COVID-19. These include, for example, an antiviral drug that was originally developed for Ebola, two malaria drugs, or combinations of drugs. The studies are flexible and are closely monitored internationally, so that unsuitable active substances are quickly discarded and new active substances are quickly included in the study. Overall, scientifically reliable results should be generated faster than usual. In addition, these studies can give as many patients as possible access to new, promising therapies.